1,721,069 research outputs found
Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region
Full text linkIntroduction: Treatment of inoperable cutaneous squamous cell carcinoma (cSCC) of the head and neck region is still debated. Case report: We report an original case of cure of cSCC of the head and neck region with weekly hypofractionated radiation therapy with megavoltage electrons prescribed for locally advanced inoperable disease. Results: Weekly hypofractionated radiotherapy assured complete regression and was well-tolerated. Conclusion: The real efficacy of this treatment in the therapeutic arsenal remains to be defined. A clinical trial is ongoing to test the use of 8 weekly fractions of 8 Gy hypofractionated RT regimens in non-resectable cSCC cases
Intra-operative radiation therapy (IORT) in recurrent head and neck cancer
No full textntraoperative radiotherapy (IORT) an innovative technique that assures the delivery of radiation immediately after surgical resection and thus directly on tumor bed, without the necessity of excessive radiation protection measures. The clinical data regarding the use of IORT in head and neck cancer are little and a comprehensive and evidence-based analysis of recurrent head and neck cancer is still pending. Despite an aggressive multidisciplinary management, in head and neck cancer it is difficult to achieve long term control and approximately 30% of patients, especially those with locally advanced disease at diagnosis, develop loco-regional failure. Independently of primary location, the vast majority of recurrences occurs at or adjacent to the original tumor sit
Induction chemotherapy in patients with anal canal cancer: a pilot study
No full textPurpose: To investigate the role of induction chemotherapy (IC) followed by definitive chemoradiotherapy in people with anal canal cancer with bulky disease at diagnosis. Patients and Methods: We assessed patient acceptability and treatment feasibility of IC in patients with bulky anal canal malignant lesions. Results: Theoretical IC advantages may include tumor downsizing and early micrometastasis eradication, without affecting compliance with subsequent standard chemoradiotherapy regimens, as a result of improvement of oxygenation and higher intramural concentration of cytotoxic drugs. Conclusion: The study design should be proven feasible, with a satisfactory patient acceptance rate and an optimized work flow. To our knowledge, this study is the first trial to investigate the use of IC in the population of patients with bulky anal canal cancer
Osteoradionecrosis: an old toxicity in the IMRT era?
No full textIntensity modulated radiation therapy (IMRT) has had a rapid growth in treatment strategy, especially for head and neck cancer (HNC), due to its well known conformal dose advantages. Osteoradionecrosis (ORN) is direct through irradiation of mandible bone and IMRT offers the potential to spare it. As we move into the era of IMRT, is ORN still a real toxicity
In response to Yavas G and Yavas C on comment on “Intensified neoadjuvant chemoradiotherapy for locally advanced rectal cancer in elderly patients: toxicity, disease control, and survival outcomes”
No full textIntensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcome
Immune check-point inhibitors and standard chemoradiotherapy in definitive head and neck cancer treatment
Full text linkIn head and neck cancer management, there is a need for tailored approaches to optimally implement clinical outcomes. Based on the assumption that efficacy and long-term toxicity are not satisfactory for standard concurrent platinum-based chemoradiotherapy, several trials have been designed to test whether induction immunotherapy and/or concomitant immunotherapy and radiotherapy result in improved survival and toxicity outcomes. Here, we present an overview of the most recent concomitant therapeutic strategies for head and neck cancer, focusing on the knowledge available regarding check-point inhibitors. The aim is to present the characteristics of the main check-point inhibitors and to summarize the clinical trials on the combination of immune check-point inhibitors and (chemo)radiotherapy in the definitive HNC setting, in order to provide a useful clinical tool for further research
Neoadjuvant strategy as initial treatment in resectable pancreatic cancer: concrete evidence of benefit.
No full textPancreatoduodenectomy remains the recommended treatment in potentially curative strategies for pancreatic carcinoma. Due to high local failure rates even after complete resection, a multi-modality treatment approach is paramount in the management of resectable disease. Despite there being insufficient evidence to recommend a specific neoadjuvant strategy, several studies have tested the use of preoperative chemoradiotherapy in this sub-group of patients, achieving promising results. The treatment is well-tolerated, with higher rates of negative margins and lower rates of lymph node positivity at resection, a decrease in local failure and benefit in overall survival. Considering the poor oncological results after primary surgical treatment, neoadjuvant strategy should be considered as a valid alternative in resectable pancreatic carcinoma
Radiotherapeutic Treatment Approaches for Brain Metastases.
No full textBrain metastases represent an important healthcare problem. Approximately 20%-40% of patients develop disease metastatic to the brain over the course of their cancer history. Palliative treatment of brain metastases requires for immediate control and, at least temporarily, a remission of the symptoms because many of the symptoms associated with brain metastases reduce the patient's quality of life. Radiation therapy is used to treat this clinical circumstance. The aim of this review is to assess the efficacy and the toxicity of radiotherapeutic treatment approaches and to provide treatment recommendation for brain metastases
- …
